Pamiparib (BGB-290) is a small molecule inhibitor of PARP1 and PARP2.<h4>Methods</h4>The PARALLEL-303 study (NCT03427814) investigated the efficacy and safety of pamiparib 60 mg orally (PO) twice daily (BID) versus placebo PO BID as maintenance therapy in patients with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line chemotherapy. Here, PARP2 is linked to gastric cancer.